Cargando…

The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges

SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancer worldwide, with an overall survival (OS) rate, all stages combined, of still <10% at 5 years. For most patients with unresectable or recurrent PDAC, few therapeutic options are available wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muller, Marie, Haghnejad, Vincent, Schaefer, Marion, Gauchotte, Guillaume, Caron, Bénédicte, Peyrin-Biroulet, Laurent, Bronowicki, Jean-Pierre, Neuzillet, Cindy, Lopez, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870260/ https://www.ncbi.nlm.nih.gov/pubmed/35205742 http://dx.doi.org/10.3390/cancers14040995

Ejemplares similares

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
por: Hilmi, Marc, et al.
Publicado: (2018)

Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ Survey
por: Caron, Bénédicte, et al.
Publicado: (2021)

Impact of the Exposome on the Epigenome in Inflammatory Bowel Disease Patients and Animal Models
por: Vieujean, Sophie, et al.
Publicado: (2022)

Is Hartmann’s Pouch an Option in the Management of Acute Severe Ulcerative Colitis?
por: Renaud, Myriam, et al.
Publicado: (2022)

Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge
por: Wils, Pauline, et al.
Publicado: (2022)

Risk-Benefit of IBD Drugs: A Physicians and Patients Survey
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Triggering Receptors Expressed on Myeloid Cells 1 : Our New Partner in Human Oncology?
por: Muller, Marie, et al.
Publicado: (2022)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Will the Quality of Research Remain the Same During the COVID-19 Pandemic?
por: Peyrin-Biroulet, Laurent
Publicado: (2020)

Methionine synthase A2756G polymorphism may predict ulcerative colitis and methylenetetrahydrofolate reductase C677T pancolitis, in Central China
por: Chen, Min, et al.
Publicado: (2008)

Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era
por: Cuny, Alix, et al.
Publicado: (2022)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
por: Bailey, Peter, et al.
Publicado: (2016)

Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma
por: Roy, Shikha, et al.
Publicado: (2021)

FAK activity in cancer‐associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer
por: Zaghdoudi, Sonia, et al.
Publicado: (2020)

Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease
por: Abreu, Maria T, et al.
Publicado: (2020)

Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
por: Danese, Silvio, et al.
Publicado: (2021)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

Metabolic Pathways as a Novel Landscape in Pancreatic Ductal Adenocarcinoma
por: Ali, Ahmad, et al.
Publicado: (2022)

The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma
por: Loch, Florian N., et al.
Publicado: (2023)

Key drug-targeting genes in pancreatic ductal adenocarcinoma
por: Sakharkar, Meena Kishore, et al.
Publicado: (2021)

Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic
por: Bonsack, Olivier, et al.
Publicado: (2023)

Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
por: Ciernikova, Sona, et al.
Publicado: (2020)

The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification
por: Yang, Yefan, et al.
Publicado: (2022)

Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma
por: Ferguson, L. Paige, et al.
Publicado: (2023)

Protecting patients with IBD during the COVID-19 pandemic
por: Fiorino, Gionata, et al.
Publicado: (2020)

Inter‐ and intra‐tumoural heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal adenocarcinoma
por: Neuzillet, Cindy, et al.
Publicado: (2019)

Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma
por: Debbabi, Inès, et al.
Publicado: (2023)

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic
por: Kotze, Paulo Gustavo, et al.
Publicado: (2021)

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nru4fv9oes2upr2s4sa441migb